Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from InfuSystem Holdings ( (INFU) ).
Following InfuSystem Holdings, Inc.’s 2026 Annual Meeting of Stockholders held on May 11, 2026, the board elected director Beverly Huss as Chairman of the Board. The company emphasized that her appointment involved no special arrangements, family relationships, or material related-party transactions, underscoring a standard governance process and a clean independence profile for the new chair.
The most recent analyst rating on (INFU) stock is a Buy with a $17.50 price target. To see the full list of analyst forecasts on InfuSystem Holdings stock, see the INFU Stock Forecast page.
Spark’s Take on INFU Stock
According to Spark, TipRanks’ AI Analyst, INFU is a Neutral.
INFU scores mid-range due to improved profitability and cash generation, plus generally constructive guidance and balance-sheet flexibility; these positives are tempered by weak technical momentum, a high P/E valuation, and revenue pressure tied to contract restructuring and near-term execution/cost risks.
To see Spark’s full report on INFU stock, click here.
More about InfuSystem Holdings
InfuSystem Holdings, Inc. operates in the medical services and equipment sector, providing infusion pumps and related healthcare services to patients and providers. The company focuses on supporting outpatient and home-based infusion therapies, working with hospitals, oncology practices, and other care settings across its U.S. network.
Average Trading Volume: 140,480
Technical Sentiment Signal: Sell
Current Market Cap: $169.7M
See more insights into INFU stock on TipRanks’ Stock Analysis page.